SCHEMBL10322346

SCHEMBL10322346

COc1cc(NCc2ccccc2)c(C(=O)O)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
ASPH Q12797 3/20 0.56
KDM8 Q8N371 3/20 0.56
RIOX2 Q8IUF8 2/20 0.56
KDM4C Q9H3R0 4/20 0.52
KDM6B O15054 1/20 0.52
KDM4A O75164 1/20 0.52
KDM4D Q6B0I6 1/20 0.52
JAK3 P52333 2/20 0.51
IRAK4 Q9NWZ3 2/20 0.51
JAK2 O60674 1/20 0.51
JAK1 P23458 1/20 0.51
TYK2 P29597 1/20 0.51
VNN1 O95497 2/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
KDM5B Q9UGL1 2/20 0.46
HTT P42858 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22140403 0.91 JAK3 (0.50) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL10330658 0.82 KDM4E (0.60) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL4409419 0.80 KDM4E (0.60) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL1715565 0.78 ALDH1A1 (0.57) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL28663574 0.78 KDM4E (0.58) KDM4EASPHKDM8RIOX2HDAC1
SCHEMBL30358579 0.78 KDM4E (0.58) KDM4EASPHKDM8RIOX2HDAC1
SCHEMBL5627204 0.77 ALDH1A1 (0.52) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL22836927 0.77 AKR1C3 (0.63) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL22140401 0.76 JAK3 (0.51) KDM4EASPHKDM8RIOX2KDM4C
SCHEMBL24157190 0.76 KDM4E (0.65) KDM4EASPHKDM8RIOX2KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 KDM4E 2930/4885ASPH 794/4885KDM8 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.